

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address. Box ISSUE FEE

ASSISTANT COMMISSIONER FOR PATENTS

WASHINGTON, D.C. 20231

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

1861/0926

MARK DELLICA

WOODCOCK WASHBURN KURTZ

MACKIEWIUZ & NORRIS

ONE LIBERTY PLACE, 45TH FLOOR

PHILADELPHIA PA 19103

APPLICA	ATION NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT		DATE MAILED
	08/789.270	01/28/97	005	SCHEINER, T	1806	09/26/97
First Named Applicant	WALDMAN.	·	\$0.00	1 Α.		

TLEOF METHODS OF AND KITS AND COMPOSITIONS FOR DIAGNOSING COLORECTAL TUMORS VENTION AND METASTASIS THEREOF

ATTY'S DOCKE	T NO.	CLASS-SUBCLASS	BATCH NO.	APPLN	. TYPE	SMALL EN	ITITY	FEE DUE	DATE DUE	
1 7.	JU-2115	435-00	7.230	S23	UTT	1TY	YES	\$645 _a 1	00 12/26	/97

HE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. ROSECUTION ON THE MERITS IS CLOSED.



HE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS PPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED.</u>

OW TO RESPOND TO THIS NOTICE:

Review the SMALL ENTITY status shown above. If the SMALL ENTITY is shown as yes, verify your current SMALL ENTITY status:

- A. If the status is changed, pay twice the amount of the FEE DUE shown and notify the Patent and Trademark Office of the change in status, or
- B. If the status is the same, pay the FEE DUE shown above.

If the SMALL ENTITY is shown as NO:

- A. Pay FEE DUE shown above, or
- B. File verified statementof Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.

Part B of this notice should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "6b" of Part B should be completed.

All communications regarding this application must give application number and batch number. Please direct all communication prior to issuance to Box ISSUE FEE unless advised to the contrary.

PORTANT REMINDER: Patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

3. PATENT AND TRADEMARK OFFICE COPY



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FILING DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO.

08/789,270

WALDMAN

18M1/0926

MARK DELUCA

PTOL-37 (Rev. 10/95)

MODDCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS ONE LIBERTY PLACE 46TH FLOOR PHILADELPHIA PA 19103

01/28/97

DATE MAILED!6

ARBITHE INE FPAPER NUMBER

09/26/97

This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS

NOTICE OF ALLOWABILITY
All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance and Issue Fee Due or other appropriate communication will be mailed in due course.
This communication is responsive to the amendment filed 9/18/97
The allowed claim(s) is/are 9-13 (renumbered as 1-5)
☐ The drawings filed on are acceptable.
Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
☐ received.
received in Application No. (Series Code/Seriat Number)
☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:
Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" of this Office action. Failure to timely comply will result in ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).
□ Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
Applicant MUST submit NEW FORMAL DRAWINGS
because the originally filed drawings were declared by applicant to be informat.
including changes required by the Notice of Draftperson's Patent Drawing Review, PTO-948, attached hereto or to Paper No
including changes required by the Notice of Draftperson's Patent Drawing Review, PTO-948, attached hereto or to Paper No including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
including changes required by the proposed drawing correction filed on
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment.
 including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson.
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. ☐ including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. ☐ Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE RATCH NUMBER and DATE of the NOTICE OF
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. In Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included.
including changes required by the proposed drawing correction filed on, which has been approved by the examiner, which has been approved by the examiner, which has been approved by the examiner same transmitter and the proposed of the drawings. Including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. □ Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included.
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s)
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s)
including changes required by the proposed drawing correction filed on
including changes required by the proposed drawing correction filed on
including changes required by the proposed drawing correction filed on, which has been approved by the examiner, which has been approved including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Indicial Draftperson

Serial Number: 08/789,270

Art Unit:

9/D

Page 2

EXAMINER'S AMENDMENT

1/23/97

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mark DeLuca on September 19, 1997.

The application has been amended as follows:

Canceled claims 14-19.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Toni R. Scheiner whose telephone number is (703) 308-3983.

9/19/97

TONI R. SCHEINER PRIMARY EXAMINER GROUP 1800

Doni R. Scheme

Serial Number: 08/789,270 Page 2

Art Unit:

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or

additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312.

To ensure consideration of such an amendment, it MUST be submitted no later than the payment

of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

Mark DeLuca on September 19, 1997.

The application has been amended as follows:

Canceled claims 14-19.

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Toni R. Scheiner whose telephone number is (703) 308-3983.

9/19/97

Doni R. Schemin